Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7799200 | 0.86 | MGLL (0.56) | SMN1; SMN2LMNAGAAL3MBTL1CYP2C19 | |
| SCHEMBL14861111 | 0.86 | GAA (0.58) | TSHRGAAAPOBEC3AAPOBEC3GL3MBTL1 | |
| SCHEMBL9190987 | 0.85 | KMT2A (0.63) | SMN1; SMN2LMNAKCNJ1KCNH2KDM4E | |
| SCHEMBL10599026 | 0.85 | TSHR (0.70) | TSHRSMN1; SMN2LMNAGAAALOX15 | |
| SCHEMBL4829258 | 0.82 | MAPT (0.59) | SMN1; SMN2LMNAGAAAPOBEC3AAPOBEC3G | |
| SCHEMBL2045374 | 0.82 | PPID (0.67) | SMN1; SMN2LMNAGAAAPOBEC3AAPOBEC3G | |
| SCHEMBL6966891 | 0.81 | PLAU (0.59) | SMN1; SMN2LMNACYP2C19CYP2C9 | |
| SCHEMBL26499969 | 0.81 | MAOB (0.62) | SMN1; SMN2LMNAGAAAPOBEC3AAPOBEC3G | |
| SCHEMBL372131 | 0.81 | PPARG (0.51) | GAAAPOBEC3AAPOBEC3GL3MBTL1CYP2C19 | |
| SCHEMBL1521016 | 0.80 | PTPRF (0.57) | TSHRSMN1; SMN2GAAAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4556480-A1 | COMPOUNDS CONSTITUTING C20-MODIFIED SALINOMYCIN DERIVATIVES, A METHOD FOR OBTAINING THE SAME, A COMPOSITION CONTAINING THE SAME AND A USE OF SAID COMPOUNDS | Fileclo Spolka Z Ograniczona Odpowiedzialnoscia (PL) | 2025-05-21 | — | — | EP | disclosed |
| US-20240294541-A1 | COMPOUNDS CONSTITUTING C20-MODIFIED SALINOMYCIN DERIVATIVES, A METHOD FOR OBTAINING THE SAME, A COMPOSITION CONTAINING THE SAME AND A USE OF SAID COMPOUNDS | FILECLO SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2024-09-05 | — | — | US | disclosed |
| CN-113166102-A | Anticancer compounds | 法马马有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | WELLSTAT BIOCATALYSIS, LLC | 2005-06-09 | — | — | US | disclosed |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | IGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| EP-0628542-B1 | Process for the preparation of organic carbamates | BAYER AG (DE) | 1997-04-09 | — | — | EP | disclosed |
| EP-0746336-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0746336-A4 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN INC (US) | 1996-07-26 | — | — | EP | disclosed |
| EP-0628542-A1 | Process for the preparation of organic carbonates | BAYER AG (DE) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | TSHR 4068/4885SMN1; SMN2 4221/4885LMNA 4566/4885 |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | TSHR 4068/4885SMN1; SMN2 4221/4885LMNA 4566/4885 |
| US-20240294541-A1 | COMPOUNDS CONSTITUTING C20-MODIFIED SALINOMYCIN DERIVATIVES, A METHOD FOR OBTAINING THE SAME, A COMPOSITION CONTAINING THE SAME AND A USE OF SAID COMPOUNDS | MRPS22, MRPS27, DHPS | TSHR 4476/4885SMN1; SMN2 2788/4885LMNA 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.